Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 8/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13616959 | 0.81 | MAOB (0.52) | HTR2BMAOBMAOACYP2D6ALDH1A1 | |
| SCHEMBL3098370 | 0.81 | MAPK14 (0.68) | NR3C2MAPK14MAOBMAOAAKR1B1 | |
| SCHEMBL15395917 | 0.80 | MAOB (0.37) | NR3C2MAPK14MAOB | |
| SCHEMBL4039496 | 0.78 | MAPK14 (0.53) | NR3C2MAPK14HTR2BMAOB | |
| SCHEMBL2251060 | 0.77 | NR3C2 (0.58) | NR3C2MAPK14HTR2BCYP3A4CYP2C9 | |
| SCHEMBL3090362 | 0.77 | NR3C2 (0.58) | NR3C2MAPK14HTR2BCYP3A4CYP2C9 | |
| SCHEMBL2251054 | 0.77 | NR3C2 (0.58) | NR3C2MAPK14HTR2BCYP3A4CYP2C9 | |
| SCHEMBL14177160 | 0.74 | NR3C2 (0.55) | NR3C2MAPK14HTR2BCYP3A4CYP2C9 | |
| SCHEMBL12065133 | 0.73 | KCNH2 (0.47) | NR3C2MAPK14HTR2BCYP3A4CYP2C9 | |
| SCHEMBL9749909 | 0.73 | AKR1B1 (0.74) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803814-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803814-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803814-B2 | Tricyclic steroid hormone nuclear receptor modulators | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| EP-1697350-B1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1697350-B1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | LILLY CO ELI (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20070037788-A1 | 5-(3,8-Difluoro-6H-dibenzo[b,e]oxepin-11-ylidenemethyl)-1-(1-ethyl-pyrrolidin-3-yl) -1,3-dihydro-benzoimidazol-2-one; antiinflammatory, antidiabetic agent; electrolytes and water retention modulator; hypotensive, hypoglycemic agent; arrhythmias, myocardial fibrosis, osteoporosis, polyuria, polydipsia | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037788-A1 | 5-(3,8-Difluoro-6H-dibenzo[b,e]oxepin-11-ylidenemethyl)-1-(1-ethyl-pyrrolidin-3-yl) -1,3-dihydro-benzoimidazol-2-one; antiinflammatory, antidiabetic agent; electrolytes and water retention modulator; hypotensive, hypoglycemic agent; arrhythmias, myocardial fibrosis, osteoporosis, polyuria, polydipsia | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037788-A1 | 5-(3,8-Difluoro-6H-dibenzo[b,e]oxepin-11-ylidenemethyl)-1-(1-ethyl-pyrrolidin-3-yl) -1,3-dihydro-benzoimidazol-2-one; antiinflammatory, antidiabetic agent; electrolytes and water retention modulator; hypotensive, hypoglycemic agent; arrhythmias, myocardial fibrosis, osteoporosis, polyuria, polydipsia | ELI LILLY AND COMPANY (US) | 2007-02-15 | — | — | US | disclosed |
| EP-1697350-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005066161-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005066161-A1 | TRICYCLIC STEROID HORMONE NUCLEAR RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037788-A1 | 5-(3,8-Difluoro-6H-dibenzo[b,e]oxepin-11-ylidenemethyl)-1-(1-ethyl-pyrrolidin-3-yl) -1,3-dihydro-benzoimidazol-2-one; antiinflammatory, antidiabetic agent; electrolytes and water retention modulator; hypotensive, hypoglycemic agent; arrhythmias, myocardial fibrosis, osteoporosis, polyuria, polydipsia | SLC5A1, REN, AQP1 | NR3C2 151/4885MAPK14 839/4885HTR2B 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.